Elizabeth Lihua Budde, MD, PhD, is an associate professor in the Division of Lymphoma, Department of Hematologic Oncology & Hematopoietic Cell Transplantation and executive director of the Enterprise Immune Effector Cell Program at City of Hope National Medical Center in Duarte, California. She specializes in the treatment and research of blood malignancies. Her scholarly focus is on immunotherapies for patients with leukemia and lymphoma, and she has clinical expertise in lymphoma, leukemia, and bone marrow and stem cell transplant.
Dr. Budde is the recipient of numerous Clinical Investigator awards and her articles have appeared in Nature Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Journal of Hematology & Oncology, and Clinical Cancer Research. As the lead investigator for several translational research studies, Dr. Budde manages an array of clinical trials and has been invited to speak at various national and international conferences. She serves on the NCCN Guidelines Panel for B Cell Lymphoma as well as Management of Immunotherapy Related Toxicities Panel and serves on several consortiums and associations, including the Association of American Cancer Institutes CAR T Working Group, Mantle Cell Lymphoma Consortium at the Lymphoma Research Foundation, American Society of Hematology, and American Society of Clinical Oncology.
Dr. Budde is board certified in medical oncology and internal medicine. She completed a fellowship at the University of Washington Fred Hutchinson Cancer Research Center and her residency at Washington University School of Medicine. She earned her medical degree and her PhD at Duke University and earned her bachelor’s degree from Tongji Medical University in China.